|Bid||620.89 x 800|
|Ask||636.80 x 1100|
|Day's range||623.12 - 641.79|
|52-week range||441.00 - 686.62|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||10.16|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.
The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.
Hennion & Walsh CIO Kevin Mahn joins Yahoo Finance Live to discuss the stock market amid heightened market volatility in recent days.